9 completed, 8 active not recruiting, 7 recruiting, 5 withdrawn. 35 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 9, Active not recruiting 8, Recruiting 7, Withdrawn 5, Terminated 4, Unknown 2 |
| Phase 2 | 11 | Completed 4, Active not recruiting 2, Recruiting 2, Withdrawn 2, Unknown 1 |
Follow Refractory B-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory B-Cell Non-Hodgkin Lymphoma trials Research Report on Refractory B-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma ONC-PluReceptor NK cells - Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-02-24 | 2026-11-03 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma LUCAR-20SP cells - Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 42 | 2024-03-14 | 2025-03-25 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy - High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-09-29 | 2026-03-05 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab - B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | ADC Therapeutics S.A. | 154 | 2022-06-17 | 2026-07-17 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) CB-010, Cyclophosphamide, Fludarabine - Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | Phase 1 | Active not recruiting | Caribou Biosciences, Inc. | 72 | 2021-05-26 | 2026-10-19 |
| Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Modified anti-CD19 CAR T cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia | Phase 1 | Unknown | Liqun Zou | 18 | 2021-03-17 | 2022-09-26 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) CD19.CAR-aNKT cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 13 | 2020-04-14 | 2026-07-13 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 |
Showing 20 of 35. Sign in to see all of them.
Lymphoma, B-Cell (35) · Lymphoma, Mantle-Cell (11) · Lymphoma, Follicular (10) · Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, T-Cell (7) · Lymphoma, Non-Hodgkin (6) · Burkitt Lymphoma (5) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma (3) · Waldenstrom Macroglobulinemia (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia (1) · Leukemia, B-Cell (1)
Hemic and Lymphatic Diseases (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphatic Diseases (35) · Lymphoproliferative Disorders (35) · Neoplasms (35) · Neoplasms by Histologic Type (35) · Lymphoma (32) · Lymphoma, Non-Hodgkin (29) · Hematologic Diseases (11) · Leukemia (7) · Leukemia, Lymphoid (6) · Chronic Disease (5) · DNA Virus Infections (5) · Disease Attributes (5)
Rituximab (7) · CT-P10 (6) · Cyclophosphamide (5) · Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Biopsy (4) · Lenalidomide (4) · fludarabine (4) · Etoposide (3) · Leukapheresis (3) · Carmustine (2) · Cytarabine (2) · MLN 8237 (2) · Melphalan (2) · Peripheral Blood Stem Cell Transplantation (2)
National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (5) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (2) · Mayo Clinic (2) · ADC Therapeutics S.A. (1) · Academic and Community Cancer Research United (1) · Affimed GmbH (1) · Barbara Ann Karmanos Cancer Institute (1) · Baylor College of Medicine (1) · CARsgen Therapeutics Co., Ltd. (1) · Caribou Biosciences, Inc. (1) · Estrella Immunopharma, Inc. (1) · Joseph Tuscano (1) · Kami Maddocks (1)
United States (28) · China (3) · Czechia (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Ajay Gopal (2) · Catherine S Diefenbach (2) · Jordan Gauthier (2) · Carlos Ramos, MD (1) · Dipenkumar Modi, M.D. (1) · Grzegorz S Nowakowski (1) · Hun Lee (1) · Jennifer E Agrusa, MD (1) · Jennifer E Amengual (1) · Jie Jin, Dr. (1) · Joseph M Tuscano (1) · Joseph Tuscano (1) · Kami Maddocks, MD (1) · Katy Rezvani (1) · Leslie L Popplewell (1)
PMID 34515338, PMID 33785483, PMID 36597128, PMID 39820359, PMID 40186077
P30CA033572 (3), P01CA044991 (2), P30CA015704 (2), P30CA016672 (2), UM1CA186689 (2), P01CA229086 (1), P30CA013330 (1), P30CA015083 (1), P30CA016058 (1), P30CA016087 (1), P30CA022453 (1), P30CA093373 (1), P50CA097274 (1), P50CA107399 (1), P50CA126752 (1)